Greg Gorman
Professor and Vice Chair, Department of Pharmaceutical, Social and Administrative Sciences and Director, Pharmaceutical Sciences Research Institute
McWhorter School of Pharmacy
Department of Pharmaceutical, Social and Administrative Sciences
2211 CHS Building 2
ggorman@samford.edu
205-726-4452

Greg Gorman joined McWhorter School of Pharmacy faculty in 2010 after working in the drug discovery/development industry for over 12 years.  Research in his laboratory is focused in both non-clinical and clinical areas of interest.  The non-clinical research has two primary goals: (1) discovery and development of adjuvants for improved bioactivation of chemotherapeutic prodrugs via enzymatic biomodulation and (2) development of a new class of herbal based aromatase inhibitors for estrogen receptor positive (ER+) breast cancer. Clinical research projects address the impact of continuous renal replacement therapy (CRRT) on the adequacy of IV dosed beta-lactam antibiotics in renally impaired pediatric patients. A second project evaluates physical compatibility of multi-port IV dosing of commonly used medications in different pediatric intensive care units.

Degrees and Certifications

  • PhD, bioanalytical chemistry, University of Georgia
  • BS, chemistry, Armstrong State College

Awards and Honors

  • Lifetime Achievement Scholarship Award 2022
  • Samford University Outstanding Scholarship Award August 2020
  • Distinguished Scholar Award in Published Scholarship, 2019
  • Superior Scholar Award in Published Scholarship, 2015
  • Scholar Award in Published Scholarship, 2014

Involvment

  • American Association of Pharmaceutical Scientist

Expertise

  • Drug metabolism
  • Chemotherapeutic pro-drug activation
  • Drug-drug and drug-herbal interactions

Publications

  • Bandi DSR, Nagaraju GP, Sarvesh S, Carstens JL, Foote JB, Graff EC, Fang YD, Keeton AB, Chen X, Valiyaveettil J, Berry KL, Bae S, Akce M, Gorman G, Yoon KJ, Manne U, Boyd MR, Buchsbaum DJ, Azmi AS, Maxuitenko YY, Piazza GA, El-Rayes BF. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Mol Cancer. 2025 Mar 13;24(1):76. doi: 10.1186/s12943-025-02288-9. PMID: 40082968; PMCID: PMC11905721.

  • Kahil, E., Jackson, A., D’Souza, B., Gorman, G., & Jumbo-Lucioni, P. (2025). Investigating the therapeutic potential of 1,2,3,4,6 penta-O-galloyl-β-D-glucose in Alzheimer’s disease: a scoping review. Natural Product Research, 1–15. https://doi.org/10.1080/14786419.2025.2477226

  • Foote JB, Mattox TE, Keeton AB, Chen Xi, Smith FT, Berry K, Holmes, TW, Wang, J, Huang C, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark F, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchbaum DJ, Yang J, Zhou G, Nurmemmedov E, Babic I, Gaponeko V, Abdekarim H, Boyd MR, Gorman G, Manne U, Bae, S, El-Rayes B, Piazza G. “A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer” Cancer Research Dec 2024 e-online ahead of print https://doi.org/10.1158/0008-5472.CAN-24-0323

  • Alamaw ED, Casey KM, Tien K, Franco BD, Gorman GS, Cotton RM, Nagamine C, Jampachaisri K, Sharp P, Pacharinsak C, Huss MK. “Carprofen Attenuates Postoperative Mechanical and Thermal Hypersensitivity after Plantar Incision in Immunodeficient NSG Mice” Comparative Medicine Apr 2024, 1;74(2):105-114.

  • Farmer SE, Arnold JA, Hughes PJ, Pan K, Gorman GS. A Continuing Pharmacy Education (CPE) Program Assessing Cannabidiol (CBD) Knowledge and Confidence Among Practicing Pharmacists. Journal of Pharmacy Practice. 2024, Vol. 37(5) 1048–1054. doi:https://doi.org/10.1177/08971900231213938

  •  Janganati, V., Salazar, P., Parks, B.J., Gorman, G.S., Prather, P.L., Peterson, E.C., Alund, A.W., Moran, J.H., Crooks, P,A. & Brents, L.K. (2023) Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats. Frontiers in Pharmacology. 14, 1123261. PMCID: PMC10204800

  • Lopez-Echeverria G, Alamaw E, Gorman G, Jampachaisri K, Huss M, Packarinsak C. “Comparing Three Formulations of Buprenorphine in an Incisional Pain Model in Mice” J. Am Assoc Lab Anim Sci. 2023 62(6):531-537.

  •  Tobacyk J, Parks BJ, Salazar P, Coward LU, Berquist MD, Gorman GS, Brents LK. “Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.” Drug Alcohol Depend. 2023;249:110832. doi:10.1016/j.drugalcdep.2023.110832.

  • Mander S, Gorman GS, Coward L, et al. The brain-penetrant cell-cycle inhibitor p28 sensitizes brain metastases to DNA-damaging agents. Neuro-oncology advances. 2023;5(1). doi:https://doi.org/10.1093/noajnl/vdad042

  •  Kadariya Y, Sementino E, Ujjawal S, Gorman G, White JM, Clapper ML, Neamati N,Miller MS, Testa JR. “Inflammation as a Chemoprevention Target in Asbestos-Induced Malignant Mesothelioma” Carcinogenesis, 2022; 43, 1137–1148.

  • Aboelella NS, Brandle C, Okoko O, Gazi MY, Ding Z, Xu H, Gorman G, Bollag R, Davilla ML, Bryan LJ, Munn DH, Piazza GA, Zhou G. “Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy” Journal for ImmunoTherapy of Cancer 2022; 10(7)e004938. doi:10.1136/jitc-2022-004938.

  • Gorman G, Coward L, Hambuchen MD. “Rapid Brain Distribution of Subcutaneously Administered Methamphetamine in Mice” European Journal of Drug Metabolism and Pharmacokinetics. 2022 48(1): 115-118. https://doi.org/10.1007/s13318-022-00801-9

Presentations

  • Madson K, Gorman GS. “In Vitro Investigations of Paclitaxel Metabolism Using Herbal Extracts” Samford University colloquium April 2025.

  • Gorman, GS. “Metabolic Biomodulation of Chemotherapeutic Prodrugs using Natural Products” Harrison School of Pharmacy, Auburn University, January 2025.

  • Arnold JA, Farmer S, Gorman GS, Hughes PJ, Pan K. “A continuing Pharmacy Education (CPE) Program Assessing the Knowledge and Confidence Among Practicing Pharmacist” AACP Meeting Auroa CO. July 2023.

  • Jackson A, Kahil E, Gorman GS, Jumbo-Lucioni. “Samford Research Colloquia, "1,2,3,4,6-Penta-O-Galloyl-β-D-Glucose (β-PGG) Mitigates Movement Deficits in a Preclinical Model of Alzheimer’s Disease," Samford University, Birmingham, AL, United States.

  •  Fella, K, Coward, L. Gorman, GS. Jumbo-Lucioni, P. 2023 Samford Research Colloquia, "Targeting Neprilysin in a pre-clinical model of Alzheimer’s disease," Samford University, Birmingham, AL, United States. (April 21, 2023).

  •  Fella, K. Coward, L., Gorman, G. S. Jumbo-Lucioni, P. P. 2023 APhA Annual Meeting, "Neprilysin Inhibition: Good for the Heart But Bad for the Brain in a pre-clinical model of Alzheimer’s disease?," American Pharmacist Association (APhA), Phoenix, AZ, United States. (March 24, 2023).

  • Nasher, A. Mainali, S., Coward, L., Gorman, G. S. Chtarbanova, S. Hoffman, J. Jumbo-Lucioni, P. , 100th Alabama Academy of Science Annual Meeting, "Behavioral deficits in an aged Drosophila model of Alzheimer’s disease respond to long-term ACE inhibition in a sex-specific manner," Alabama Academy of Science, Birmingham, AL, United States. (March 8, 2023).

  •  Farmer S, Gorman G. “Pharmacology of commercially available CBD oils and investigations of potential drug interactions with commonly prescribed opioids, anti-seizure and anticoagulant” Continuing Education for Jefferson Coounty Pharmacist Association November 2021.

  • Hambuchen MD, Findley DL, Coward L, Gorman G. 2021 Symposium on Substance Use Research oral presentation, “Association Between Brain and Serum Methamphetamine Disposition and Methamphetamine-Induced Locomotor Activity After Subcutaneous Administration in Mice,” Virtual Meeting (November 11, 2021).

  •  Parker SJ, Gorman GS, Cates ME, Cruthirds D, Coward L. “Effects of Different Cannabidiol (CBD) Oils on the Anti-Seizure Medication Phenytoin” Mental Health Clinician (2021) 11 (2): 86. Presented at the CPNP 2021 Annual Meeting April 2021

Research

  • Drug metabolism
  • Drug-drug
  • Drug-herbal interactions
  • Aromatase inhitors
  • Chemotherapeutic pro-drug activation